| Popis: |
Monoclonal antibodies (mAbs) are the largest class of therapeutic proteins. Owing to their versatile structure and function, mAbs are used for a wide range of therapeutic indications including oncology, immunology, neurology, metabolic, and cardiovascular diseases. Over the past three decades, more than 50 mAbs have been approved in the United States and Europe, and by 2020, about 70 mAb-based products are expected to be in the market (Ecker DM, Jones SD, Levine HL, MAbs 7:9–14, 2015). In 2017, 5 of the top 10 best-selling drugs in the global market are mAbs (Urquhart L, Nat Rev Drug Discov 17:232, 2018). In addition, several new therapeutic modalities based on mAbs including antibody-drug conjugates (ADCs), bispecific antibodies, and Fc fusion proteins have been approved or are in clinical trials. |
